Skip to Main Content

WASHINGTON — The National Institutes of Health on Thursday announced a $215 million public-private partnership with 11 pharmaceutical companies in what the agency bills as a significant next step in its cancer moonshot.

The Partnership for Accelerating Cancer Therapies, or PACT, is a five-year agreement to push ahead with research that seeks to “identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer,” the agency said.


The Foundation for the National Institutes of Health, a congressionally established nonprofit that manages public-private partnerships involving the NIH, will oversee the initiative.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!